Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Ascendis Pharma A/S's quarterly P/E stands at 5.8x.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -55.72 | 5.77 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 18.02 | 14.72 | 13.35 | 14.19 | 17.45 | 23.17 | 11.83 | 37.80 | 54.31 | 22.42 | 12.95 | 27.43 | 26.47 |
| — | -36.5% | +12.8% | -62.5% | -67.9% | +3.3% | -8.6% | +37.8% | +105.2% | -49.9% | -82.7% | -70.9% | -87.4% | |
| P/B Ratio | — | 30.21 | — | — | — | — | — | — | — | — | — | — | 77.38 |
| — | — | — | — | — | — | — | — | — | — | — | — | +806.7% | |
| P/FCF | 285.69 | — | 48.57 | 1443.48 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | 127.78 | 228.78 | 206.44 | — | — | 438.85 | — | — | — | — | — | — |
| — | — | -47.9% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | 149.51 | 340.31 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Ascendis Pharma A/S's operating margin was 10.1% in Q1 2026, up 6.1 pp QoQ and up 113.3 pp YoY. The trailing four-quarter average of -3.6% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 10.6% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 91.4% | 88.9% | 89.5% | 80.1% | 82.6% | 91.9% | 80.6% | 68.2% | 92.1% | 85.9% | 84.6% | 72.7% |
| — | +10.6% | -3.3% | +11.0% | +17.5% | -10.3% | +7.1% | -4.7% | -6.3% | +6.8% | +10.6% | -4.8% | -11.7% | |
| Operating Margin | -18.9% | 10.1% | 4.0% | 5.1% | -33.5% | -103.2% | 0.2% | -167.3% | -370.2% | -51.2% | -26.6% | -279.8% | -297.2% |
| — | +109.7% | +1715.8% | +103.1% | +90.9% | -101.4% | +100.8% | +40.2% | -24.6% | +88.0% | +95.9% | +70.4% | +87.1% | |
| Net Margin | -31.7% | 255.2% | -13.6% | -28.5% | -24.6% | -93.7% | -22.1% | -171.5% | -303.9% | -136.6% | -63.1% | -337.7% | -256.2% |
| — | +372.3% | +38.7% | +83.4% | +91.9% | +31.4% | +64.9% | +49.2% | -18.6% | +58.6% | +93.0% | +69.4% | +80.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | 392.8% | — | — | — | — | — | — | — | — | — | — | -104.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | -724.2% | |
| ROA | -17.7% | 38.7% | -2.7% | -5.4% | -3.6% | -8.4% | -3.4% | -10.7% | -14.0% | -16.1% | -10.2% | -19.1% | -13.6% |
| — | +558.0% | +20.0% | +49.2% | +74.2% | +47.5% | +66.9% | +44.0% | -3.3% | -49.2% | +41.7% | -47.1% | -125.6% | |
| ROIC | -69.1% | 4.2% | 7.6% | 7.8% | -31.7% | -47.2% | 0.2% | -91.5% | -98.3% | -23.3% | -15.4% | -61.5% | -60.7% |
| — | +108.8% | +3304.0% | +108.5% | +67.7% | -102.4% | +101.4% | -48.7% | -61.8% | +46.0% | +49.6% | -139.6% | -139.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Ascendis Pharma A/S's Debt/EBITDA ratio is 30.4x, down from 59.8x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 1.84 | — | — | — | — | — | — | — | — | — | — | 7.80 |
| — | — | — | — | — | — | — | — | — | — | — | — | +826.0% | |
| Debt / EBITDA | — | 30.42 | 59.76 | 54.19 | — | — | 176.33 | — | — | — | — | — | — |
| — | — | -66.1% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.04 | 1.00 | 1.04 | 1.03 | 1.02 | 1.04 | 1.17 | 1.16 | 0.74 | 0.83 | 0.95 | 3.44 | 3.52 |
| — | -4.3% | -11.3% | -11.2% | +37.7% | +25.2% | +22.5% | -66.3% | -79.0% | -79.6% | -82.3% | -54.4% | -63.5% | |
| Quick Ratio | 0.76 | 0.72 | 0.76 | 0.73 | 0.69 | 0.71 | 0.84 | 0.84 | 0.44 | 0.54 | 0.67 | 2.56 | 2.65 |
| — | +1.0% | -10.4% | -14.1% | +56.6% | +31.4% | +25.7% | -66.9% | -83.3% | -83.7% | -85.5% | -62.6% | -69.8% | |
| Interest Coverage | -1.69 | 0.37 | 0.16 | -2.91 | -0.06 | -1.09 | -0.75 | -2.87 | -4.56 | -0.67 | -1.06 | -5.59 | -12.06 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Deep dive into ASND consensus models and risk factors.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ASND stock.
Ascendis Pharma A/S's current P/E is -55.7x. The average P/E over the last 1 quarters is 5.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ascendis Pharma A/S's current operating margin is -18.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ascendis Pharma A/S's business trajectory between earnings reports.